LLY vs ABBV — Key Metrics

Metric LLY (ELI LILLY & CO) ABBV (ABBVIE INC)
Price1382.75286.01
Market Cap1.3 Trillion505.56 Billion
P/E (TTM)44.8249.06
P/B (Quarterly)32.09-109.235
P/S (TTM)15.047.66
Net Profit Margin (TTM)31.915.7
Gross Margin (TTM)83.673.7
ROE (TTM)83.6-201.0
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

ELI LILLY & CO
vs
 
ABBVIE INC
 
ELI LILLY & CO
vs
 
ABBVIE INC
Performance Comparison
AI Model Recommendation
LLY · ELI LILLY & CO

Underperform

-30
UnderperformOutperform
ABBV · ABBVIE INC

Outperform

44
UnderperformOutperform
Recommendation Summary

Stock LLY is projected to underperform the market, stock ABBV is projected to outperform the market. Upfront Recommendation: ABBV.

Financial Metrics
Prices delayed ~15 min
LLY Metrics ABBV
$1,382.75 Price $286.01
— Market Capitalization —
44.82 Price to Earnings Ratio 49.06
15.04 Price to Sales 7.66
66.16 Price to FCF Ratio 26.79
17.99 Price to Gross Profit 10.39
84.59 Price to R&D 50.75
19.93 Price to Current Assets 13.49

LLY vs ABBV at a glance

ELI Lilly & CO (LLY) and Abbvie INC (ABBV) are both Drug Manufacturers - General companies in the Healthcare sector. LLY is the larger, at $1.3 trillion in market value against $505.6 billion for ABBV, about 2.6 times the size.

On trailing-twelve-month figures, LLY trades at 44.8 times trailing earnings and ABBV at 49.1; net profit margins are 31.9% and 15.7%.

The Upfront Investment model currently rates LLY Underperform and ABBV Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.